600 patients66,869 observations120 daysLIVE

Patient P-01505

Synthetic patientNBL-101 · Day 107 · 75+ · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
69%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 31 NP-02 recommendedDietary Support Protocol NP-02
  3. Day 32 Patient acceptedStarted NP-02 in the companion
  4. Day 42 GI symptom burden −21% vs expectedDietary Support Protocol NP-02
  5. Day 48 Tolerance state changedUnstable → Improving
  6. Day 49 Trajectory diverged from predictionObserved response fell below the model's expected path.
  7. Day 55 GI-04 recommendedGI Support Protocol GI-04
  8. Day 56 Patient acceptedStarted GI-04 in the companion
  9. Day 64 GI symptom burden −19% vs expectedGI Support Protocol GI-04
  10. Day 70 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 49.

Primary contributors, last 14 days
  • GI instability+6
  • Inflammatory activity+6
  • Toxicity+6
  • Nutritional resilience-5
  • Treatment adherence+2

What helped?

  • Dietary Support Protocol NP-02Day 31
    Result: symptom burden −21%
  • GI Support Protocol GI-04Day 55
    Result: symptom burden −19%
LIFE OS recommendation
Monitoring Escalation ME-01
83%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 100% showed improvement
  • median effect visible after 3 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
51.7/100
improving · -2.0 vs previous 14 d
Toxicity
Blood
38.4/100
worsening · +2.1 vs previous 14 d
Sleep quality
Wearable
27.7/100
stable · +0.5 vs previous 14 d
Energy level
Daily log
2.6/10
worsening · -0.2 vs previous 14 d
Stress level
Daily log
6.3/10
stable · -0.1 vs previous 14 d
Steps
Wearable
7,705
stable · +203 vs previous 14 d
Adherence
Companion
53.1 %
worsening · -3.2 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards failing · 26 from the failing basin, 60 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 71%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 71%
  • CR-01 Clinician Review
    100% improved among 8 similar · onset 5 d · confidence 71%
Would not help
  • Keep fat low
    GI +2.9 next day on high-intake days · n 19
  • Keep simple carbs low
    GI +2.4 next day on high-intake days · n 21
  • Keep alcohol low
    GI +2.4 next day on high-intake days · n 20
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +2.9detractor · 95%
  • Simple carbohydrates
    +2.4detractor · 95%
  • Alcohol
    +2.4detractor · 95%
  • Histamine load
    +2.1detractor · 75%
  • Insoluble fibre
    +1.9detractor · 59%
  • Spicy / capsaicin
    -0.7no signal · 24%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 90
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 52 and rising
    • WearableSleep 5.2 h, below personal baseline
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 56
  • Autonomic recovery 45
    • WearableResting HR 79 bpm
    • WearableShort sleep window
  • Drug metabolism and exposure 35
    • DNADPYD *2A → slower clearance
  • Butyrate / short-chain fatty acid production 20
    • Daily logFibre intake low in recent food logs
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • DPYD *2A heterozygous
    Slower drug clearance
  • CYP2D6 Intermediate metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.3 · butyrate capacity 48/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiNormal
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
56 ms
Sleep
5.5 h
Steps
7,272
Resting HR
77 bpm
Daily log: GI score 52, nutritional resilience 43, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0132739%S01GI-04improved56
P-0168837%S01GI-04improved40
P-0181334%S01NP-02no change40
P-0131029%S0157
P-0182124%S0158
P-0182324%S0157
P-0184624%S0137
P-0187724%S01CR-01improved67
P-0163541%S02GI-04improved49
P-0145237%S02GI-04improved46
P-0145931%S0251
P-0149824%S0256